

D. Xavier: None Declared, F. Wagner: None Declared, A. Balduino de Souza: None Declared, M. O. Pozzolo Pedro: None Declared, D. Soler Lopes: None Declared, M. Carbajal Tamez: None Declared, J. Quevedo Shareolder of: Instituto de Neurociencias Dr. Joao Quevedo, Grant / Research support from: LivaNova; and receives copyrights from Artmed Editora, Artmed Panamericana, and Elsevier/Academic Press, Consultant of: EMS, Libbs, and Eurofarma, Speakers bureau of: Myriad Neuroscience and AbbVie., M. Teranishi: None Declared

O098

The 'time' in lifetime: age-stratification and its impact on immune-based depression treatment

E. Van Assche^{1,*}, C. Hohoff¹ and B. T. Baune^{1,2,3}

¹Department of Psychiatrie, University of Münster, Münster, Germany; ²Department of Psychiatry, University of Melbourne and ³Department of Psychiatry, The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.351

Introduction: Depression is increasingly linked to immunological processes. Therefore, immune-based therapies, e.g., celecoxib, are being tested as augmenting treatment strategies. Many physiological processes during life are also linked to immunological changes. We tested the hypothesis that age affects treatment efficacy in a randomized controlled sample treated with the anti-inflammatory agent Celecoxib.

Objectives: We test the combined role of age and an anti-inflammatory augmentation treatment for treatment response in depression. For a more in depth understanding we investigated the role of six methylation-based cell-types in these immunological processes in a second step.

Methods: 113 individuals with a diagnosis of major depressive disorder were included in our analyses ($M_{age}=44$, 56% women, $M_{MADRS}=27.7$). All patients were treated with Vortioxetine and recruited stratified by high sensitive C-Reactive Protein (hsCRP; ≤ 3 vs. > 3 mg/L) > 3 mg/L). Based on a randomized controlled design, augmentation with Celecoxib was administered to 55 patients. A second assessment was performed after 6 weeks of treatment ($M_{MADRS_{6W}}=20.2$). Cell type compositions of neutrophils, monocytes, B-cells, CD4+ and CD8+ Lymphocytes, and natural killer cells (NK), were estimated based on epigenome-wide DNA methylation markers (Illumina Infinium MethylationEPIC 850k BeadChip) using the Houseman method. Analyses were performed with linear regression models with $MADRS_{6W}$ as outcome. Our hypothesis was tested in the full sample. The additional analyses were performed stratified by age. All models were corrected for sex, hsCRP, and depression severity at baseline.

Results: Our analysis showed a statistically significant interaction between age and treatment condition on depression outcome ($p=0.040$), with significant main effects for both variables in the model (intervention: $p=0.045$, age: $p=0.022$). Sex and hsCRP were

no statistically significant contributors. The intersection was identified at 45.5 years. Younger individuals treated with celecoxib showed a more pronounced reduction in MADRS ($M_{reduction}=-9.6$), than older individuals treated with the same condition ($M_{reduction}=-5.5$). The stratified individuals younger than 45 years, showed that neutrophils were associated with better treatment outcome ($p=0.028$), whereas for individuals older than 45 years this was the case for B-cells and NK cells ($p=0.011$, and $p<0.001$, respectively).

Conclusions: Our results indicate that immunological profiles in depression and in relation to treatment may be age-dependent, which can have major consequences for treatment success with anti-inflammatory augmenting strategies. Replication in an independent sample is needed to confirm the role of age in immune-focused treatment strategies for depression.

Disclosure of Interest: None Declared

O099

A randomized controlled trial of supervised group exercise therapy in patients with clinical depressive and anxiety disorders: the challenge of patient compliance

Q. Zhai^{1,2,*}, M. Folkesson³, C. Hörnsten⁴, J. Persson^{5,6}, S. Montgomery^{1,7,8} and Y. Freund-Levi^{1,9,10,11}

¹School of Medical Sciences, Örebro University; ²Department of Psychiatry, Örebro University Hospital; ³School of Health Sciences, Örebro University, Örebro; ⁴Department of Clinical Sciences, Psychiatry, Umeå University, Umeå; ⁵School of Behavioural, Social and Legal Sciences, Örebro University, Örebro; ⁶Department of Neurobiology, Care Sciences and Society; ⁷Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; ⁸Department of Epidemiology and Public Health, University College London, London, United Kingdom; ⁹Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm; ¹⁰Department of Geriatrics, Örebro University Hospital, Örebro and ¹¹Department of Geriatrics, Södertälje Hospital, Södertälje, Sweden

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.352

Introduction: Depression and anxiety are global mental health concerns and contribute significantly to the global burden of human disease. Although psychotherapies and antidepressant drugs are effective and commonly used treatments for depression and anxiety, some patients do not achieve full remission of their symptoms and there remains a risk of residual symptoms.

Objectives: To validate effect of supervised group exercise therapy in outpatient treatment of depressive and anxiety disorders.

Methods: A total of 126 individuals were screened for elevated depressive and anxiety symptoms. 86 participants aged between 18 and 65 years (Median=33 years; IQR 15; 62.8 % females) were randomly assigned to exercise group (EX, N=43) or relaxation group (REL, N=43). EX was planned to receive 36 sessions and REL 12 sessions during a 12-week intervention. Depressive

symptoms were measured using Montgomery-Åsberg Depression Rating Scale (MADRS and MADRS-S) and anxiety symptoms using Becks Anxiety Inventory (BAI) at pre-, mid- and post-intervention.

The study is registered on ClinicalTrials.gov Register for RCT's (NCT04714528).

Results: Intention-to-treat analyses showed that both groups improved significantly in depressive and anxiety symptoms (MADRS: EX from 24.5 ± 7.4 to 15.8 ± 8.3 points, REL from 22.8 ± 6.4 to 16.6 ± 7.8 points. MADRS-S: EX from 27.6 ± 7.2 to 19.6 ± 8.1 points, REL from 26.3 ± 7.1 to 18.7 ± 9.5 points. BAI: EX from 25.0 ± 12.2 to 16.4 ± 9.9 points, REL from 24.3 ± 12.4 to 17.0 ± 12.6 points). However, there was no statistically significant difference between the groups in the degree of improvement. In addition, there was a high and differential attrition rate (51.2 % in EX vs 20.9 % in REL, $p=0.007$). It took longer than expected for the exercise group to finish the intervention (EX 19.2 ± 5.1 weeks vs REL 14.8 ± 4.0 weeks). Attrition analysis showed that individuals that had student as their main occupation were more likely to drop out and participants with sleep medication were more likely to adhere to interventions.

Image 1:





Image 2:



Conclusions: The study reflects the challenges of outpatient, activity-based treatments for mild to moderate depressive and anxiety disorders regarding compliance, despite great efforts were made to keep the participants' motivation throughout the study. Although both groups improved in depression and anxiety symptoms similarly, due to the lack of control group with no active treatment, it is difficult to assess possible placebo effect from this study. The differential bias from attrition and compliance makes it difficult to draw definitive conclusions.

Disclosure of Interest: None Declared